Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: Final 5-year report of the LEADERS (limus eluted from a durable versus erodable stent coating) randomized, noninferiority trial

JACC: Cardiovascular Interventions

Volumn 6, Issue 8, 2013, Pages 777-789

  Serruys, Patrick W ^a   Farooq, Vasim ^a   Kalesan, Bindu ^b   De Vries, Ton ^c   Buszman, Pawel ^d   Linke, Axel ^e   Ischinger, Thomas ^f   Klauss, Volker ^g   Eberli, Franz ^d   Wijns, William ^h   Morice, Marie Claude ⁱ   Di Mario, Carlo ^j   Corti, Roberto ^k   Antoni, Diethmar ^l   Sohn, Hae Y ^m   Eerdmans, Pedro ⁿ   Rademaker Havinga, Tessa ^c   Van Es, Gerrit Anne ^c   Meier, Bernhard ^o   Jüni, Peter ^b   Windecker, Stephan ^o   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c CARDIALYSIS   (Netherlands)

^d American Heart of Poland ^*  (Switzerland)

^e UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^f Kardiologie im Zentrum   (Germany)

^g Kardiologie Innenstadt   (Germany)

^h OLV HOSPITAL   (Belgium)

ⁱ INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l KLINIKUM BOGENHAUSEN   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ Biosensors International Group Ltd   (Switzerland)

^o UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

biodegradable polymer drug eluting stents durable polymer stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYMER; RAPAMYCIN; TICLOPIDINE; UMIROLIMUS;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BIODEGRADABLE IMPLANT; CAUSE OF DEATH; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STENT THROMBOSIS;

ACADEMIC RESEARCH CONSORTIUM; ACS; ACUTE CORONARY SYNDROME; ARC; BARE-METAL STENT(S); BES; BIODEGRADABLE POLYMER; BIOLIMUS-ELUTING STENT(S); BMS; CI; CONFIDENCE INTERVAL; DES; DRUG-ELUTING STENT(S); DRUG-ELUTING STENTS; DURABLE POLYMER; KAPLAN-MEIER; KM; MACE; MAJOR ADVERSE CARDIAC EVENTS; MI; MYOCARDIAL INFARCTION; PATIENT-ORIENTED COMPOSITE ENDPOINT; PCI; PERCUTANEOUS CORONARY INTERVENTION; POCE; RATE RATIO(S); RR; SES; SIROLIMUS-ELUTING STENT(S); ST; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEMI; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; TVR;

ABSORBABLE IMPLANTS; AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882803077     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.04.011     Document Type: Article

References (50)

1. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
2. L.D. Hillis, P.K. Smith, and J.L. Anderson 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 58 2011 e123 e210
3. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
4. M.R. Patel Appropriate use criteria to reduce underuse and overuse: striking the right balance J Am Coll Cardiol 60 2012 1885 1887
5. V. Farooq, B.D. Gogas, and P.W. Serruys Restenosis: delineating the numerous causes of drug-eluting stent restenosis Circ Cardiovasc Interv 4 2011 195 205
6. P.W. Serruys, G. Sianos, and A. Abizaid The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES) J Am Coll Cardiol 46 2005 253 260 (Pubitemid 40966852)
7. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510 (Pubitemid 46986103)
8. A.V. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441 (Pubitemid 46717966)
9. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
10. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
11. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
12. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455 discussion 1455 (Pubitemid 46648381)
13. L. Raber, L. Wohlwend, and M. Wigger Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial Circulation 123 2011 2819 2828
14. L. Raber, S. Baumgartner, and H.M. Garcia Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study J Am Coll Cardiol Intv 5 2012 946 957
15. S.-J. Park, S.-J. Kang, R. Virmani, M. Nakano, and Y. Ueda In-stent neoatherosclerosis: a final common pathway of late stent failure J Am Coll Cardiol 59 2012 2051 2057
16. G. Nakazawa, F. Otsuka, and M. Nakano The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
17. S. Garg, and P.W. Serruys Coronary stents: looking forward J Am Coll Cardiol 56 2010 S43 S78
18. E. Grube, and L. Buellesfeld BioMatrix biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease Expert Rev Med Devices 3 2006 731 741 (Pubitemid 46017613)
19. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
20. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
21. J. Wykrzykowska, P. Serruys, and P. Buszman The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS) EuroIntervention 7 2011 789 795
22. G. Sianos, M.A. Morel, and A.P. Kappetein The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease EuroIntervention 1 2005 219 227
23. P.W. Serruys, Y. Onuma, and S. Garg Assessment of the SYNTAX score in the Syntax study EuroIntervention 5 2009 50 56
24. P.W. Serruys, M.C. Morice, and A.P. Kappetein Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
25. V. Farooq, S. Brugaletta, and P.W. Serruys The SYNTAX score and SYNTAX-based clinical risk scores Semin Thorac Cardiovasc Surg 23 2011 99 105
26. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
27. P.W. Serruys, A.T. Ong, and L.A. van Herwerden Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial J Am Coll Cardiol 46 2005 575 581 (Pubitemid 41132680)
28. D.R. Holmes Jr., D.J. Kereiakes, and S. Garg Stent thrombosis J Am Coll Cardiol 56 2010 1357 1365
29. D.P. Faxon Very late stent thrombosis and late target lesion revascularization: no end in sight Circulation 125 2012 562 564
30. K. Fujii, S.G. Carlier, and G.S. Mintz Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study J Am Coll Cardiol 45 2005 995 998 (Pubitemid 40432428)
31. T. Geisler, C. Zurn, and R. Simonenko Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J 31 2010 59 66
32. S. Cook, E. Ladich, and G. Nakazawa Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
33. S. Cook, P. Wenaweser, and M. Togni Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation Circulation 115 2007 2426 2434 (Pubitemid 46717965)
34. A.V. Finn, and F. Otsuka Neoatherosclerosis: a culprit in very late stent thrombosis Circ Cardiovasc Interv 5 2012 6 9
35. D.E. Cutlip, D.S. Baim, and K.K. Ho Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials Circulation 103 2001 1967 1971 (Pubitemid 32322224)
36. S. Windecker, and B. Meier Late coronary stent thrombosis Circulation 116 2007 1952 1965 (Pubitemid 350287091)
37. E.J. Armstrong, D.N. Feldman, and T.Y. Wang Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis J Am Coll Cardiol Intv 5 2012 131 140
38. T. Kimura, T. Morimoto, and K. Kozuma Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) Circulation 122 2010 52 61
39. S. Bangalore, S. Kumar, and M. Fusaro Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
40. V. Farooq, Y. Vergouwe, and L. Raber Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score Eur Heart J 33 2012 3098 3104
41. V. Farooq, D. van Klaveren, and E.W. Steyerberg Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II Lancet 381 2013 639 650
42. C.S. Fox, K. Matsushita, and M. Woodward Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis Lancet 380 2012 1662 1673
43. M. Tonelli, P. Muntner, and A. Lloyd Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 2012 807 814
44. V. Farooq, Y. Vergouwe, and P. Genereux Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) Score J Am Coll Cardiol Intv 6 2013 737 745
45. B. Kalesan, T. Pilgrim, and K. Heinimann Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 977 987
46. F. Otsuka, M. Nakano, E. Ladich, F.D. Kolodgie, and R. Virmani Pathologic etiologies of late and very late stent thrombosis following first-generation drug-eluting stent placement Thrombosis 2012 2012 608593
47. L. Raber, H. Kelbaek, and M. Ostoijc Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design EuroIntervention 7 2012 1435 1443
48. L. Raber, H. Kelbaek, and M. Ostojic Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
49. M. Sabate, A. Cequier, and A. Iniguez Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial Lancet 380 2012 1482 1490
50. R.J. Little, R. D'Agostino, and M.L. Cohen The prevention and treatment of missing data in clinical trials N Engl J Med 367 2012 1355 1360